أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

arrow generics limited - cabergoline - tablets - 4 milligram

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

pharmacia laboratories limited - cabergoline - tablets - 4 milligram

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

pfizer private limited - cabergoline - tablet - 0.5 mg - cabergoline 0.5 mg

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

apotex nz ltd - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose magnesium stearate - indicated for the inhibition of physiological lactation soon after delivery. (1) after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. (2) after still birth or abortion.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

a-s medication solutions - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings ).

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

a-s medication solutions - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings).

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

a-s medication solutions - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. (see warnings ) - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (see warnings )

إسرائيل - الإنجليزية - Ministry of Health

trima israel pharmaceutical products maabarot ltd - cabergoline - tablets - cabergoline 2 mg - cabergoline - cabergoline - parkinson's disease. combination therapy with l-dopa and as monotherapy for newly diagnosed illness.

اليابان - الإنجليزية - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - cabergoline - white tablet, diameter: 5.5 mm, thickness: 2.9 mm

اليابان - الإنجليزية - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - cabergoline - white tablet, diameter: 5.5 mm, thickness: 2.9 mm